国产药VC方案与GC方案治疗晚期非小细胞肺癌的对比观察  

Comparative Study of VC and GC Regimen in Advanced Stage Nonsmall Cell lung Cancer

作　　者：莫海鹰[1] 王健[1] 董维[1] 于新发[1] 

机构地区：[1]佛山市顺德区第一人民医院内五科,广东佛山528300

出　　处：《国际医药卫生导报》2005年第18期47-49,共3页International Medicine and Health Guidance News

摘　　要：目的比较国产药VC方案(盖诺+卡铂)与GC方案(泽菲+卡铂)治疗晚期(Ⅲb～Ⅳ期)非小细胞肺癌(NSCLC)患者的疗效及毒副作用。方法69例晚期初治的NSCLC患者中,33例用VC方案治疗,36例用GC方案治疗。结果VC、GC组近期疗效(CR+PR)分别为42.4%、38.9%,两组差异无显著性(P>0.05),中位分别为9个月和10个月(P>0.05)。VC组骨髓抑制明显,Ⅲ～Ⅳ度WBC下降率为51.5%,而GC组为27.8%(P<0.05),VC组静脉炎和周围神经炎发生率较高。结论VC与GC方案治疗晚期NSCLC疗效相近,中位生存期相似,GC组骨髓抑制相对较轻,不易发生静脉炎及周围神经炎,生活质量较好。Objective To compare the efficacy and toxicity between VC regimen and GC regimen in patients with advanced NSCLC （stage Ⅲb-Ⅳ）.Methods sixty nine advanced non-small cell lung cancer patients were divided into two groups： group VC（33 cases） was treated with VC regimen （Vinovelbine＋CBP）, group GC（36 cases） was treated with GC regimen （Gemcitabine＋CBP）. Results Response rate （CR＋PR） were 42.4% for VC regimen and 38. 9% for GC regimen respectively. No statistical significant difference was noted in response rate between the two groups （P〉0.05）. Median survival time were 9 months for VC and lO months for GC（P〉0.05）. The major toxicity was bone marrow suppression. Grade Ⅲ-Ⅳ leukopenia occurred in 51.5% of the VC group and 27.8% of the GC group. There was a significant difference （P〈0.05） between two groups. Grade Ⅲ-Ⅳ thrombocytopenia was 6.1% in VC group and 16.2% in GC group （P〉0. 05）, Conclusion Similar response rates and median survival time were seen in patients with NSCLC treated with VC and GC regimens, Compare with VC group, bone marrow suppression was mind and superficial phlebitis and peripheral neuritis were rare in GC group, The quality of llfe of patient treated with GC regimen was better than that of patient treated with VC regimen.

关 键 词：非小细胞肺癌 对比研究 盖诺 泽菲 卡铂 

分 类 号：R734.2[医药卫生—肿瘤]